Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Healthcare Customer Relationship Management (CRM) Market Poised for Robust Expansion, Reaching USD 27.6 Billion by 2033 with a Strong 12.2% CAGR: Market Research Intellect

The Healthcare Customer Relationship Management (CRM) market has witnessed significant expansion, reaching a valuation of USD 12.5 billion in 2024 and projected to grow substantially to USD 27.6 ...